New blood test could replace painful biopsies for breast cancer patients
NCT ID NCT04480814
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new blood test (liquid biopsy) that looks for cancer DNA in the blood of 30 women with advanced ER+/HER2- breast cancer. The goal was to see if the test can accurately find cancer mutations without needing a traditional tissue biopsy. The results will help doctors monitor cancer changes over time with a simple blood draw.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
30 people
The number who actually took part.
- Started
-
Oct 2019
- Finished
-
Feb 2022
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
120 with metastatic breast cancer 30 healthy subjects
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Female aged ≥ 18 years of age. 2. Histological confirmed ER+/HER2- metastatic Breast Cancer prior to beginning a treatment 3. Life expectancy permits participation to the study. 4. Available tumor tissue sample for molecular analysis. 5. Signed informed consent form. Exclusion Criteria: 1. Female younger than 18 years old. 2. History of another malignancy within 3 years or current 2nd primary malignancy. 3. Patients that have not signed the informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aretaieio University Hospital of Athens
Athens, Attica, 11528, Greece
-
Metropolital Hospital
Piraeus, Piraeus, 18547, Greece
-
University General Hospital of Alexandroupoli
Alexandroupoli, Alexandroupolis, 68100, Greece
-
University General Hospital of Athens Attikon
Athens, Attica, 124 62, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?